Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98

Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86

Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol (2006) 6.22

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol (2014) 5.89

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (2016) 5.79

Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature (1992) 5.47

Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature (1993) 5.47

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 3.10

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90

Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature (1987) 2.85

Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature (2015) 2.76

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 2.63

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology (2013) 2.60

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res (2007) 2.20

Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol (2009) 2.04

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97

Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist (2008) 1.85

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2012) 1.82

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med (2014) 1.80

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res (2015) 1.80

A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res (2012) 1.74

Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev (2015) 1.53

Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res (2005) 1.49

A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol (2014) 1.44

Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci (1998) 1.39

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer (2013) 1.35

A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res (2010) 1.30

Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene (2004) 1.26

Autoimmunity associated with immunotherapy of cancer. Blood (2011) 1.22

Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm (2012) 1.16

Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol (2011) 1.15

Antigen processing by autoreactive B cells promotes determinant spreading. Cell Mol Immunol (2005) 1.09

Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol (2012) 1.09

A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg (2013) 1.03

Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice. Prostate (2010) 0.96

Therapeutic vaccines: the ultimate personalized therapy? Hum Vaccin Immunother (2012) 0.94

A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res (2014) 0.93

Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proc Natl Acad Sci U S A (2014) 0.91

Single-epitope DNA vaccination prevents exhaustion and facilitates a broad antiviral CD8+ T cell response during chronic viral infection. J Immunol (2004) 0.89

Role of ES cell-expressed Ras (ERas) in tumorigenicity of gastric cancer. Am J Pathol (2010) 0.88

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol (2016) 0.88

Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs (2015) 0.86

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis (2014) 0.86

Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci (2014) 0.85

Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients. Immunotherapy (2011) 0.85

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl (2014) 0.84

Role of the ERas gene in gastric cancer cells. Oncol Rep (2013) 0.81

Cancer immunology - development of novel anti-cancer therapies. Swiss Med Wkly (2015) 0.81

Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol (2015) 0.80

Epitope-specific antibody levels in tuberculosis: biomarkers of protection, disease, and response to treatment. Front Immunol (2014) 0.80

Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications. Am Soc Clin Oncol Educ Book (2013) 0.79

T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol (2016) 0.78

Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother (2014) 0.75

Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments. Neoplasia (2014) 0.79